Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of IDEC-C2B8 (rituximab) in active rheumatoid arthritis with inadequate response or intolerance to prior therapy
jRCT2011220026Phase 3Completed
- Sponsor
- Nippon Zenyaku Kogyo Co., Ltd.
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing IDEC-C2B8 (rituximab) with Placebo (2 arms). Primary endpoint: ACR20 response at Week 24. Started Dec 2022; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2011220026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011220026.